摘要
本文总结了不同的靶标,如5α-还原酶,17β-羟化类固醇脱氢酶,7α-羟化酶,雄激素受体和蛋白激酶A对前列腺癌和良性前列腺增生的治疗的重要性。众所周知,双氢睾酮(DHT)与雄激素依赖性疾病的发展有关。目前,一些研究小组正在尝试开发新的甾体类和非甾体分子为了抑制DHT合成和生物反应。本文还讨论了文献报道中有关于描述新化合物的潜在治疗以及主要抑制5α-还原酶的新药的最新研究。
关键词: 良性前列腺增生,前列腺癌,5-α还原酶,17β-羟基类固醇脱氢酶,蛋白激酶A,雄激素受体,脱氢表雄酮衍生物,非渗透性睾酮结合物,G蛋白,蛋白激酶A
Current Medicinal Chemistry
Title:Recent Advances in Drug Design and Drug Discovery for Androgen- Dependent Diseases
Volume: 23 Issue: 8
Author(s): Marisa Cabeza, Araceli Sánchez-Márquez, Mariana Garrido, Aylín Silva and Eugene Bratoeff
Affiliation:
关键词: 良性前列腺增生,前列腺癌,5-α还原酶,17β-羟基类固醇脱氢酶,蛋白激酶A,雄激素受体,脱氢表雄酮衍生物,非渗透性睾酮结合物,G蛋白,蛋白激酶A
摘要: This article summarizes the importance of different targets such as 5α-reductase, 17β-HSD, CYP17A, androgen receptor and protein kinase A for the treatment of prostate cancer and benign prostatic hyperplasia. It is a well known fact that dihydrotestosterone (DHT) is associated with the development of androgen-dependent afflictions. At the present time, several research groups are attempting to develop new steroidal and non-steroidal molecules with the purpose of inhibiting the synthesis and biological response of DHT. This review also discusses the most recent studies reported in the literature that describe the therapeutic potential of novel compounds, as well as the new drugs, principally inhibitors of 5α-reductase.
Export Options
About this article
Cite this article as:
Marisa Cabeza, Araceli Sánchez-Márquez, Mariana Garrido, Aylín Silva and Eugene Bratoeff , Recent Advances in Drug Design and Drug Discovery for Androgen- Dependent Diseases, Current Medicinal Chemistry 2016; 23 (8) . https://dx.doi.org/10.2174/0929867323666160210125642
DOI https://dx.doi.org/10.2174/0929867323666160210125642 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Immune Response and Immunotherapy: Live Attenuated Listeria monocytogenes (Lm)-LLO Immunotherapy for the Treatment of Prostate Cancer
Current Cancer Therapy Reviews miR-149 as a Potential Molecular Target for Cancer
Current Medicinal Chemistry High Throughput Screening for Colorectal Cancer Specific Compounds
Combinatorial Chemistry & High Throughput Screening Garlic-Derived Allyl Sulfides in Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Congenital Malformations Attributed to Prenatal Exposure to Cyclophosphamide
Anti-Cancer Agents in Medicinal Chemistry Pluronic-Based Core/Shell Nanoparticles for Drug Delivery and Diagnosis
Current Medicinal Chemistry A Fresh Prospect of Extracellular Matrix Hydrolytic Enzymes and Their Substrates
Current Pharmaceutical Design Anticancer Effect of a Curcumin Derivative B63: ROS Production and Mitochondrial Dysfunction
Current Cancer Drug Targets Advances in Oncolytic Virus Therapy for Glioma
Recent Patents on CNS Drug Discovery (Discontinued) ARRDC3 Inhibits the Progression of Human Prostate Cancer Through ARRDC3-ITGβ4 Pathway
Current Molecular Medicine Development of Arene Ruthenium Antitumor Complexes
Mini-Reviews in Medicinal Chemistry Advances in Quantitative Mass Spectrometry Analysis: Weighing in on Isotope Coding and Label-Free Approaches for Expression and Functional Proteomics
Current Analytical Chemistry Hyaluronic Acid as a Protein Polymeric Carrier: An Overview and a Report on Human Growth Hormone
Current Drug Targets ADDENDUM: Increased Akt Signaling Resulting from the Loss of Androgen Responsiveness in Prostate Cancer. Dulinska-Litewka J, McCubrey JA, Laidler P. Curr. Med. Chem., 2013, 20(1), 144-157.
Current Medicinal Chemistry Low Testosterone Levels and Metabolic Syndrome in Aging Male
Current Pharmaceutical Design Pathophysiology and Treatment of Nonfamilial Hyperparathyroidism
Recent Patents on CNS Drug Discovery (Discontinued) Transient Opening of the Blood-Brain Barrier by Vasoactive Peptides to Increase CNS Drug Delivery: Reality Versus Wishful Thinking?
Current Neuropharmacology Ribonucleotide Reductase: A Critical Enzyme for Cancer Chemotherapy and Antiviral Agents
Recent Patents on Anti-Cancer Drug Discovery Epithelial-Mesenchymal Plasticity of Breast Cancer Stem Cells: Implications for Metastasis and Therapeutic Resistance
Current Pharmaceutical Design Skeletal Effects of Drugs to Treat Cancer
Current Drug Safety